Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marinus Pharmaceuticals, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The investigation is focused on whether Marinus' board of directors made materially false and misleading statements regarding the company's business and operations [2]. - The class action complaint was filed on June 5, 2024, covering a class period from March 17, 2021, to May 7, 2024 [1]. - Allegations include the understatement of risks related to the RAISE trial and the failure to disclose potential consequences of not meeting early-stopping criteria [2]. Group 2: Contact Information - Long-term stockholders of Marinus are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and the ongoing investigation [3][6]. - Contact can be made via email or telephone, with no cost or obligation to the stockholders [3].

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Group 1: Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of RxSight is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Group 2: Allegations and Financial Performance - The class action alleges that RxSight failed to disclose adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - The complaint claims that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, related to the company's secondary public offering on May 21, 2025 [1][2] - The allegations state that Sable Offshore Corp. misled investors by claiming it had restarted oil production off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can remain absent class members if they choose not to participate [3] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [4]

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - The allegations state that Centene misled investors about its business prospects, particularly regarding projected revenue and enrollment rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a significant stock price decline of over 40% from $56.65 to $44.78 per share [3] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5] - Interested parties can sign up for notifications regarding the class action settlement or alerts on corporate wrongdoing [6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1][3]. Group 1: Company Financial Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. - Following this announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [2]. Group 2: Class Action Allegations - The class action complaint alleges that Maravai's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [3]. - Specific allegations include inadequate internal controls over financial reporting related to revenue recognition, inaccurate revenue recognition during fiscal 2024, and overstated goodwill [3]. - The complaint asserts that the positive statements made by the defendants regarding the company's business lacked a reasonable basis due to these undisclosed issues [3].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations - The lawsuit claims that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole as a treatment for SCA [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The revelations from the lawsuit are expected to have a significant negative impact on Biohaven's business and financial condition [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance Biotherapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [2][3]. Group 1: Legal Investigation - The investigation is focused on whether Iovance's board of directors provided misleading information regarding the company's growth potential while concealing material adverse facts [3]. - A class action complaint was filed against Iovance on May 15, 2025, covering the period from May 9, 2024, to May 8, 2025 [2]. Group 2: Financial Performance - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance of the iCTC and lower-than-expected Proleukin sales [4]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its business prospects and financial guidance [1][2]. Allegations - The complaint claims that Centene's management created a false impression of reliable information regarding projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [2]. - A preliminary analysis indicated that over two-thirds of Centene's marketplace share showed disappointing enrollment and increased morbidity, contradicting the company's optimistic reports [2]. Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states was lower than anticipated, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share, marking a decline of over 40% in just one day [3].